uniQure to Participate in Multiple Upcoming Industry Conferences
March 29 2019 - 7:00AM
uniQure to Participate in Multiple Upcoming Industry
Conferences
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that it will participate in the following
upcoming conferences in April:
- Stifel First Annual CNS Day in Boston, Mass.
° Matt Kapusta, chief executive officer at
uniQure, will participate in a panel discussion, “Gene Therapy
Strategies in CNS,” on Monday, April 1 at 10:00 a.m. ET.
- Guggenheim Rare Disease & Gene Therapy Day in
Boston, Mass.° Matt Kapusta will attend and
participate in one-on-one investor meetings throughout the day on
Tuesday, April 2.
- H.C. Wainwright Global Life Sciences
Conference in London,
England° Sander van Deventer, M.D., Ph.D.,
chief scientific officer at uniQure, will attend and participate in
one-on-one investor meetings on Tuesday, April 9.
- EASL International Liver Congress in Vienna,
Austria° Valerie Sier-Ferreira, Ph.D.,
principal scientist of immunology research at uniQure, will present
“Lipid nanoparticle pre-treatment improves adeno-associated virus
diffusion in the primate liver and enables an increase of
therapeutic transgene expression” on Thursday, April 11 at 10:00
a.m. CET.° Anna Majowicz, Ph.D., scientist at uniQure, will
present “Adeno-associated virus-serotype-specific transduction
patterns in mice and non-human primates liver tissue: Implications
for therapeutic efficacy” on April 11 at the 10:00 a.m. CET poster
session.
- Kempen Life Science Conference in Amsterdam, the
Netherlands° Sander van Deventer will attend
and participate in investor one-on-one meetings on Tuesday, April
16.
- Alliance for Regenerative Medicine (ARM) Meeting on the
Med in Barcelona, Spain° Jonathan Garen, chief
business officer at uniQure, will present a corporate update on
Tuesday, April 23 at 11:15 a.m. CET.
- American Society of Gene and Cell Therapy (ASGCT) 21st
Annual Meeting in Washington, D.C.° uniQure
will deliver multiple data presentations at the meeting, which
takes place Monday, April 29 through Thursday, May 2. Specific
details to follow when the meeting abstracts are released.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary and partnered gene therapies to treat patients with
hemophilia, Huntington’s disease and other severe genetic diseases.
www.uniQure.com
uniQure Contacts
For Investors: |
|
For Media: |
|
|
|
Maria E. Cantor |
Eva M. Mulder |
Tom Malone |
Direct: 339-970-7536 |
Direct: +31 20 240 6103 |
Direct: 339-970-7558 |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jul 2023 to Jul 2024